{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:22:00Z","timestamp":1767846120073,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Fundaci\u00f3n Instituto para la Mejora de la Asistencia Sanitaria"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2803-0","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T12:20:26Z","timestamp":1508242826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain"],"prefix":"10.1186","volume":"17","author":[{"given":"M.","family":"Sanchez-Luna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Burgos-Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Oyag\u00fcez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Figueras-Aloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"S\u00e1nchez-Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Carbonell-Estrany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"2803_CR1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","volume":"375","author":"H Nair","year":"2010","unstructured":"Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545\u201355.","journal-title":"Lancet"},{"key":"2803_CR2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40121-016-0123-0","volume":"5","author":"L Bont","year":"2016","unstructured":"Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, et al. Defining the epidemiology and burden of severe respiratory Syncytial virus infection among infants and children in western countries. Infect Dis Ther. 2016;5:271\u201398.","journal-title":"Infect Dis Ther"},{"key":"2803_CR3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1185\/03007995.2015.1136606","volume":"32","author":"M Sanchez-Luna","year":"2016","unstructured":"Sanchez-Luna M, Elola FJ, Fernandez-Perez C, Bernal JL, Lopez-Pineda A. Trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004\u20132012. Curr Med Res Opin. 2016;32:693\u20138.","journal-title":"Curr Med Res Opin"},{"key":"2803_CR4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/path.4462","volume":"235","author":"RJ Pickles","year":"2015","unstructured":"Pickles RJ, DeVincenzo JP. Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis. J Pathol. 2015;235:266\u201376.","journal-title":"J Pathol"},{"key":"2803_CR5","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.282.15.1440","volume":"282","author":"DK Shay","year":"1999","unstructured":"Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980\u20131996. JAMA. 1999;282:1440\u20136.","journal-title":"JAMA"},{"key":"2803_CR6","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1097\/PCC.0000000000000850","volume":"17","author":"P Gupta","year":"2016","unstructured":"Gupta P, Beam BW, Rettiganti M. Temporal trends of respiratory Syncytial virus-associated hospital and ICU admissions across the United States. Pediatr Crit Care Med. 2016;17:e343\u201351.","journal-title":"Pediatr Crit Care Med"},{"key":"2803_CR7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588\u201398.","journal-title":"N Engl J Med"},{"key":"2803_CR8","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095\u2013128.","journal-title":"Lancet"},{"issue":"2","key":"2803_CR9","doi-asserted-by":"crossref","first-page":"020416","DOI":"10.7189\/jogh.05.020416","volume":"5","author":"T Shi","year":"2015","unstructured":"Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA, Zar HJ, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 2015;5(2):020416.","journal-title":"J Glob Health"},{"key":"2803_CR10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40121-016-0130-1","volume":"5","author":"J Figueras-Aloy","year":"2016","unstructured":"Figueras-Aloy J, Manzoni P, Paes B, Sim\u00f5es EA, Bont L, Checchia PA, et al. Defining the risk and associated morbidity and mortality of severe respiratory Syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease. Infect Dis Ther. 2016;5:417\u201352.","journal-title":"Infect Dis Ther"},{"key":"2803_CR11","doi-asserted-by":"crossref","first-page":"e0150416","DOI":"10.1371\/journal.pone.0150416","volume":"11","author":"A Pisesky","year":"2016","unstructured":"Pisesky A, Benchimol EI, Wong CA, Hui C, Crowe M, Belair MA, et al. Incidence of hospitalization for respiratory Syncytial virus infection amongst children in Ontario, Canada: a population-based study using validated health administrative data. PLoS One. 2016;11:e0150416.","journal-title":"PLoS One"},{"key":"2803_CR12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/pai.2006.19.26","volume":"19","author":"B Al-Shawwa","year":"2006","unstructured":"Al-Shawwa B, Al-Huniti N, Abu-Hasan M. Respiratory Syncytial virus Bronchiolitis and risk of subsequent wheezing: a matter of severity. Pediatric Asthma Allergy & Immunology. 2006;19:26\u201330.","journal-title":"Pediatric Asthma Allergy & Immunology"},{"key":"2803_CR13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/01.inf.0000136869.21397.6b","volume":"23","author":"J Figueras-Aloy","year":"2004","unstructured":"Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group. Case\u2013control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33\u201335 weeks in Spain. Pediatr Infect Dis J. 2004;23:815\u201320.","journal-title":"Pediatr Infect Dis J"},{"key":"2803_CR14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/INF.0b013e3181710990","volume":"27","author":"J Figueras-Aloy","year":"2008","unstructured":"Figueras-Aloy J, Carbonell-Estrany X, Quero-Jim\u00e9nez J, Fern\u00e1ndez-Colomer B, Guzm\u00e1n-Caba\u00f1as J, Echaniz-Urcelay I, et al. FLIP-2 study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27:788\u201393.","journal-title":"Pediatr Infect Dis J"},{"key":"2803_CR15","first-page":"10(5)","volume":"8","author":"X Carbonell-Estrany","year":"2015","unstructured":"Carbonell-Estrany X, P\u00e9rez-Yarza EG, Garc\u00eda LS, Guzm\u00e1n Caba\u00f1as JM, B\u00f2ria EV, Atienza BB, IRIS (Infecci\u00f3n Respiratoria Infantil por Virus Respiratorio Sincitial) Study Group. Long-term burden and respiratory effects of respiratory Syncytial virus hospitalization in preterm infants-the SPRING study. PLoS One. 2015;8:10(5).","journal-title":"PLoS One"},{"key":"2803_CR16","unstructured":"The European Medicines Agency Synagis summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000257\/WC500056908.pdf . Accesed 4 Nov 2016."},{"key":"2803_CR17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","volume":"368","author":"MO Blanken","year":"2013","unstructured":"Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"2803_CR18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpeds.2007.02.032","volume":"151","author":"EA Simoes","year":"2007","unstructured":"Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151(1):34\u201342.","journal-title":"J Pediatr"},{"key":"2803_CR19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1542\/peds.2013-0982","volume":"132","author":"S Yoshihara","year":"2013","unstructured":"Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Sim\u00f5es EA, et al. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013;132:811\u20138.","journal-title":"Pediatrics"},{"issue":"1","key":"2803_CR20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/INF.0b013e318235455b","volume":"31","author":"B Resch","year":"2012","unstructured":"Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, et al. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J. 2012;31(1):e1\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2803_CR21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3111\/13696990903316961","volume":"12","author":"M Nuijten","year":"2009","unstructured":"Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ. 2009;12(4):291\u2013300.","journal-title":"J Med Econ"},{"issue":"10","key":"2803_CR22","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1651-2227.2011.02309.x","volume":"100","author":"K Neovius","year":"2011","unstructured":"Neovius K, Buesch K, Sandstr\u00f6m K, Neovius M. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatr. 2011 Oct;100(10):1306\u201314.","journal-title":"Acta Paediatr"},{"issue":"1","key":"2803_CR23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00019053-200725010-00006","volume":"25","author":"MJ Nuijten","year":"2007","unstructured":"Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. PharmacoEconomics. 2007;25(1):55\u201371.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"2803_CR24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2191-1991-3-18","volume":"3","author":"A Bentley","year":"2013","unstructured":"Bentley A, Filipovic I, Gooch K, B\u00fcsch K. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. Health Econ Rev. 2013;3(1):18.","journal-title":"Health Econ Rev"},{"issue":"5","key":"2803_CR25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3111\/13696998.2012.690013","volume":"15","author":"PJ Mahadevia","year":"2012","unstructured":"Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ. 2012;15(5):987\u201396.","journal-title":"J Med Econ"},{"issue":"5","key":"2803_CR26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3111\/13696998.2012.672942","volume":"15","author":"LB Weiner","year":"2012","unstructured":"Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ. 2012;15(5):997\u20131018.","journal-title":"J Med Econ"},{"issue":"10","key":"2803_CR27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/archpedi.160.10.1070","volume":"160","author":"NO Elhassan","year":"2006","unstructured":"Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160(10):1070\u20136.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2803_CR28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1157\/13092505","volume":"65","author":"P L\u00e1zaro y de Mercado","year":"2006","unstructured":"L\u00e1zaro y de Mercado P, Figueras Aloy J, Dom\u00e9nech Mart\u00ednez E, Ech\u00e1niz Urcelay I, Closa Monasterolo R, Wood MA, et al. La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infecci\u00f3n por virus respiratorio sincitial en prematuros de 32\u201335 semanas en Espa\u00f1a. An Pediatr. 2006;65:316\u201324.","journal-title":"An Pediatr"},{"key":"2803_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10198-009-0206-x","volume":"11","author":"MJ Nuijten","year":"2010","unstructured":"Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010;11:105\u201315.","journal-title":"Eur J Health Econ"},{"key":"2803_CR30","unstructured":"Agencia de Evaluaci\u00f3n de Tecnolog\u00eda Sanitaria de. Efectividad, seguridad y eficiencia de palivizumab en la prevenci\u00f3n de la infecci\u00f3n por el virus respiratorio sincitial en prematuros. Technical Report 2014. Seville. http:\/\/www.aetsa.org\/publicacion\/efectividad-seguridad-y-eficiencia-del-palivizumab-en-la-prevencion-de-la-infeccion-por-el-virus-respiratorio-sincitial-en-prematuros . Accessed 01 Nov 2016."},{"key":"2803_CR31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care Programmes","author":"M Drummonds","year":"2005","unstructured":"Drummonds M, Sculpher M. Methods for the economic evaluation of health care Programmes. 3rd ed. Oxford: Oxford University Press; 2005. p. 14\u2013291.","edition":"3"},{"issue":"2","key":"2803_CR32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","volume":"24","author":"J L\u00f3pez Bastida","year":"2010","unstructured":"L\u00f3pez Bastida J, Oliva J, Anto\u00f1anzas F, Garc\u00eda-Alt\u00e9s A, Gisbert R, Mar J, et al. Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias. Gac Sanit. 2010;24(2):154\u201370.","journal-title":"Gac Sanit"},{"key":"2803_CR33","first-page":"13","volume":"68","author":"J Figueras-Aloy","year":"2010","unstructured":"Figueras-Aloy J, Carbonell-Estrany X, Quero-Jim\u00e9nez J, Fern\u00e1ndez-Colomer B, Guzm\u00e1n-Caba\u00f1as J, Echaniz-Urcelay I, et al. Efectividad del palivizumab en la prevenci\u00f3n de la infecci\u00f3n por virus respiratorio sincitial en prematuros de 32.1 a 35.0 semanas de gestaci\u00f3n en Espa\u00f1a. Acta Pediatr Esp. 2010;68:13\u20138.","journal-title":"Acta Pediatr Esp"},{"key":"2803_CR34","unstructured":"General Council of Official Pharmaceutical Collegues Bot Plus 2.0. Available at URL: https:\/\/botplusweb.portalfarma.com\/ . Accessed 4 Nov 2016."},{"key":"2803_CR35","unstructured":"Royal Decree-Law 8\u20132010. Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. http:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010-8228.pdf ; Accessed 4 Nov 2016."},{"key":"2803_CR36","unstructured":"Consulting O. Base de datos de costes sanitarios eSalud. Barcelona: Oblikue Consulting; 2016. http:\/\/esalud.oblikue.com\/ . Accessed 11 Feb 2016."},{"key":"2803_CR37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.anpedi.2010.10.006","volume":"74","author":"AJ Blasco Bravo","year":"2011","unstructured":"Blasco Bravo AJ, P\u00e9rez-Yarza EG, L\u00e1zaro y de Mercado P, Bonillo Perales A, D\u00edaz Vazquez CA, Moreno Gald\u00f3 A. Coste del asma en pediatr\u00eda en Espa\u00f1a: un modelo de evaluaci\u00f3n de costes basado en la prevalencia. An Pediatr (Barc). 2011;74:145\u201353.","journal-title":"An Pediatr (Barc)"},{"issue":"7","key":"2803_CR38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/adc.2003.036129","volume":"89","author":"A Greenough","year":"2004","unstructured":"Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89(7):673\u20138.","journal-title":"Arch Dis Child"},{"issue":"1","key":"2803_CR39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/intqhc\/mzh086","volume":"17","author":"CF Chiou","year":"2005","unstructured":"Chiou CF, Weaver MR, Bell MA, Lee TA, JWl K. Development of the multi-attribute pediatric asthma health outcome measure (PAHOM). Int J Qual Health Care. 2005;17(1):23\u201330.","journal-title":"Int J Qual Health Care"},{"key":"2803_CR40","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/PCC.0b013e3182070990","volume":"12","author":"PA Checchia","year":"2011","unstructured":"Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011;12:580\u20138.","journal-title":"Pediatr Crit Care Med"},{"key":"2803_CR41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF03320838","volume":"5","author":"F Catal\u00e1 L\u00f3pez","year":"2008","unstructured":"Catal\u00e1 L\u00f3pez F, Garc\u00eda-Alt\u00e9s A. Algunas consideraciones metodol\u00f3gicas en la evaluaci\u00f3n econ\u00f3mica de intervenciones preventivas: un debate abierto. PharmacoEconomics Span Res Art. 2008;5:61\u20135.","journal-title":"PharmacoEconomics Span Res Art"},{"key":"2803_CR42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","volume":"16","author":"JA Sacrist\u00e1n","year":"2002","unstructured":"Sacrist\u00e1n JA, Oliva J, Del Llano J, Prieto L, Pinto JL. \u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a? Gac Sanit. 2002;16:334\u201343.","journal-title":"Gac Sanit"},{"key":"2803_CR43","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Castilla I, Valc\u00e1rcel Nazco C, Garc\u00eda-P\u00e9rez L, Linertov\u00e1 R, Serrano-Aguilar P. Valor Monetario de un A\u00f1o de Vida Ajustado por Calidad: Estimaci\u00f3n emp\u00edrica del coste de oportunidad en el Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluaci\u00f3n del Servicio Canario de la Salud: Informes de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias; 2015. http:\/\/www3.gobiernodecanarias.org\/sanidad\/scs\/contenidoGenerico.jsp?idDocument=e690e0c1-cbed-11e5-a9c5-a398589805dc&idCarpeta=ce590e62-7af0-11e4-a62a-758e414b4260 . Accessed 10 Jan 2017"},{"key":"2803_CR44","doi-asserted-by":"crossref","unstructured":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV study group. Pediatrics. 1998;102(3 Pt 1):531\u20137.","DOI":"10.1542\/peds.102.3.531"},{"issue":"Suppl 5","key":"2803_CR45","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1067\/S0022-3476(03)00513-4","volume":"143","author":"JS Sampalis","year":"2003","unstructured":"Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143(Suppl 5):150\u20136.","journal-title":"J Pediatr"},{"issue":"6","key":"2803_CR46","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10198-011-0326-y","volume":"13","author":"JM Rodr\u00edguez Barrios","year":"2012","unstructured":"Rodr\u00edguez Barrios JM, P\u00e9rez Alc\u00e1ntara F, Crespo Palomo C, Gonz\u00e1lez Garc\u00eda P, Ant\u00f3n De Las Heras E, Brosa Riestra M. The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications. Eur J Health Econ. 2012;13(6):723\u201340.","journal-title":"Eur J Health Econ"},{"key":"2803_CR47","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1542\/peds.2014-1666","volume":"134","author":"American Academy of Pediatrics Committee on Infectious Diseases. American Academy of Pediatrics Bronchiolitis Guidelines Committee","year":"2014","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases. American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620\u201338.","journal-title":"Pediatrics"},{"key":"2803_CR48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.anpedi.2014.10.016","volume":"82","author":"J Figueras Aloy","year":"2015","unstructured":"Figueras Aloy J, Carbonell Estrany X, Comit\u00e9 de Est\u00e1ndares de la SENeo. Update of recommendations on the use of palivizumab as prophylaxis in RSV infections. An Pediatr. 2015;82:199. e1-2","journal-title":"An Pediatr"},{"key":"2803_CR49","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/INF.0000000000000808","volume":"34","author":"R Yogev","year":"2015","unstructured":"Yogev R, Krilov LR, Fergie JE, Weiner LB. Re-evaluating the new committee on infectious diseases recommendations for Palivizumab use in premature infants. Pediatr Infect Dis J. 2015;34:958\u201360.","journal-title":"Pediatr Infect Dis J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T20:58:07Z","timestamp":1719521887000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2803-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2803"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2803-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]},"article-number":"687"}}